GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Schrodinger Inc (STU:43Z) » Definitions » Float Percentage Of Total Shares Outstanding

Schrodinger (STU:43Z) Float Percentage Of Total Shares Outstanding : 54.73% (As of May. 11, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Schrodinger Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Schrodinger's float shares is 40.16 Mil. Schrodinger's total shares outstanding is 73.38 Mil. Schrodinger's float percentage of total shares outstanding is 54.73%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Schrodinger's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Schrodinger's Institutional Ownership is 54.31%.


Schrodinger Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Schrodinger's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=40.16/73.38
=54.73%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Schrodinger Business Description

Industry
Traded in Other Exchanges
Address
1540 Broadway, 24th Floor, New York, NY, USA, 10036
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Schrodinger Headlines

No Headlines